Biopharma Daily Stock Updates - 02/01/21

$XBI $159.62 +4.41% 📈

COVID:

$AMPE +15% - AMPIO ANNOUNCES EARLY POSITIVE DATA IN PHASE 1 TRIAL OF INHALED AMPION IN COVID-19 RESPIRATORY DISTRESS

$DVAX +62% - Dynavax and CEPI Announce $99 Million in Funding for CpG 1018 Adjuvant Manufacturing to Support the Global COVID-19 Response

$DVAX +62% - Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate

$IMNM +18% - Immunome’s Research Reveals a Broad Super Responder Memory B Cell Response to the SARS-CoV-2 Virus

$SRNE +15% - Update to 01/26/21 COVI-MSC™ Press Release: Fourth Patient Also Released From Hospital Following Third Infusion of Stem Cells

PIPELINE:

$ADMS +15% - Adamas Announces FDA Approval for Second Indication for GOCOVRI® as an Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes

$MIRM +5% - Mirum Pharmaceuticals Announces Completion of Rolling NDA Submission for Maralixibat in Alagille Syndrome

$KDMN +5% - Kadmon Announces Publication of Preclinical Data Demonstrating Anti-PD-L1/IL-15 Fusion Protein KD033 Achieves Robust Anti-Tumor Response

$SESN +2% - Sesen Bio Announces Successful Application Orientation Meeting (AOM) with the FDA for Vicineum™

$ADMA +10% - ADMA Biologics Receives FDA Approval for ADMA BioCenters Plasma Collection Facility in Knoxville, TN

$ARQT +30% - Arcutis Announces Positive Topline Results from Pivotal DERMIS-1 and -2 Phase 3 Trials of Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis

$RMI +1% - Rockwell Medical Announces Submission of Triferic® New Drug Application in South Korea by Partner, Jeil Pharmaceutical Co., Ltd.

$CNCE -28% - CONCERT PHARMACEUTICALS ANNOUNCES RESULTS FROM CTP-692 PHASE 2 TRIAL IN PATIENTS WITH SCHIZOPHRENIA

$GRTS -5% - Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure

$ZGNX +2% - Zogenix’s FINTEPLA® (Fenfluramine) Oral Solution Now Available in Germany for the Treatment of Seizures in Dravet Syndrome

FINANCIAL:

$VIE +52% - Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio

$ARQT +30% - Arcutis Biotherapeutics Announces Proposed Public Offering of Common Stock

$ADMS +15% - Adamas Announces Settlement of Patent Litigation with Zydus

$MNOV + 1% - Issued $20 million private placement

$MNOV +1% - MediciNova Announces Closing of US$20 Million Private Placement Transaction